Tags

Type your tag names separated by a space and hit enter

Cognitive impairment in Alzheimer's disease is modified by APOE genotype.
Dement Geriatr Cogn Disord 2007; 24(2):98-103DG

Abstract

AIM

We examined whether impairment in specific cognitive domains in Alzheimer's disease (AD) differed according to APOE genotype and age at onset.

METHODS

Cognitive functions of 229 consecutive AD patients were assessed using Visual Association Test (VAT), Memory Impairment Screen+ (MIS+), VAT object naming, fluency test and Trail Making Test (TMT). Dementia severity was assessed using MMSE. ANOVAs were performed with APOE genotype and age at onset as independent variables and sex, education and MMSE as covariates.

RESULTS

28% of patients were APOE epsilon4-negative, 58% heterozygous and 14% homozygous. A significant association between APOE genotype and VAT and MIS+ was found when correcting for sex and education. An interaction effect between APOE genotype and age at onset on VAT and VAT object naming was found, with young carriers performing worse than young noncarriers. By contrast, when additionally correcting for MMSE, a significant association between APOE genotype and VAT object naming, TMT-A and TMT-B was found, with noncarriers performing worse than carriers.

CONCLUSION

Memory was more impaired among APOE epsilon4 carriers than among noncarriers. By contrast, naming, executive functions and mental speed were more impaired among APOE epsilon4 noncarriers. This suggests that the APOE genotype modifies the clinical phenotype in terms of cognitive impairment in AD.

Authors+Show Affiliations

Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands. ae.vdvlies@vumc.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17596691

Citation

van der Vlies, Annelies E., et al. "Cognitive Impairment in Alzheimer's Disease Is Modified By APOE Genotype." Dementia and Geriatric Cognitive Disorders, vol. 24, no. 2, 2007, pp. 98-103.
van der Vlies AE, Pijnenburg YA, Koene T, et al. Cognitive impairment in Alzheimer's disease is modified by APOE genotype. Dement Geriatr Cogn Disord. 2007;24(2):98-103.
van der Vlies, A. E., Pijnenburg, Y. A., Koene, T., Klein, M., Kok, A., Scheltens, P., & van der Flier, W. M. (2007). Cognitive impairment in Alzheimer's disease is modified by APOE genotype. Dementia and Geriatric Cognitive Disorders, 24(2), pp. 98-103.
van der Vlies AE, et al. Cognitive Impairment in Alzheimer's Disease Is Modified By APOE Genotype. Dement Geriatr Cogn Disord. 2007;24(2):98-103. PubMed PMID: 17596691.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cognitive impairment in Alzheimer's disease is modified by APOE genotype. AU - van der Vlies,Annelies E, AU - Pijnenburg,Yolande A L, AU - Koene,Teddy, AU - Klein,Martin, AU - Kok,Astrid, AU - Scheltens,Philip, AU - van der Flier,Wiesje M, Y1 - 2007/06/26/ PY - 2007/01/07/accepted PY - 2007/6/29/pubmed PY - 2007/11/1/medline PY - 2007/6/29/entrez SP - 98 EP - 103 JF - Dementia and geriatric cognitive disorders JO - Dement Geriatr Cogn Disord VL - 24 IS - 2 N2 - AIM: We examined whether impairment in specific cognitive domains in Alzheimer's disease (AD) differed according to APOE genotype and age at onset. METHODS: Cognitive functions of 229 consecutive AD patients were assessed using Visual Association Test (VAT), Memory Impairment Screen+ (MIS+), VAT object naming, fluency test and Trail Making Test (TMT). Dementia severity was assessed using MMSE. ANOVAs were performed with APOE genotype and age at onset as independent variables and sex, education and MMSE as covariates. RESULTS: 28% of patients were APOE epsilon4-negative, 58% heterozygous and 14% homozygous. A significant association between APOE genotype and VAT and MIS+ was found when correcting for sex and education. An interaction effect between APOE genotype and age at onset on VAT and VAT object naming was found, with young carriers performing worse than young noncarriers. By contrast, when additionally correcting for MMSE, a significant association between APOE genotype and VAT object naming, TMT-A and TMT-B was found, with noncarriers performing worse than carriers. CONCLUSION: Memory was more impaired among APOE epsilon4 carriers than among noncarriers. By contrast, naming, executive functions and mental speed were more impaired among APOE epsilon4 noncarriers. This suggests that the APOE genotype modifies the clinical phenotype in terms of cognitive impairment in AD. SN - 1420-8008 UR - https://www.unboundmedicine.com/medline/citation/17596691/Cognitive_impairment_in_Alzheimer's_disease_is_modified_by_APOE_genotype_ L2 - https://www.karger.com?DOI=10.1159/000104467 DB - PRIME DP - Unbound Medicine ER -